Antibodies News and Research

RSS

Development of SARS-CoV-2 antibody escape variants in an immunocompromised individual

A new study published in mBio discusses the microevolution of SARS-CoV-2.

31 Aug 2021

Does SARS-CoV-2 infection protect against reinfection?

A new review showed that the protective effect of prior SARS-CoV-2 infection is at least equivalent to that of vaccination.

31 Aug 2021

Researchers identify biomarkers for rare, serious complication in children with COVID-19

The study focused on multisystem inflammatory syndrome in children (MIS-C), an inflammatory response involving multiple organs that can occur weeks after infection with SARS-CoV-2, the virus that causes COVID-19.

31 Aug 2021

$1.3 million in NIH funding to enable drug delivery technology research

Two National Institute of Health grants totaling over $1.3 million will enable research into antibody-mediated drug delivery technology for the treatment of cancer and autoimmune disorders. L. Nathan Tumey, assistant professor of pharmaceutical sciences at Binghamton University, State University of New York, is the Principal Investigator on both grants -; $1.2 million from the National Institute of General Medical Sciences and $150,000 from the National Institute of Allergy and Infectious Diseases.

31 Aug 2021

mRNA COVID-19 vaccines induce high antibody titers with significant neutralizing potency in saliva

Scientists from the USA and Canada have recently demonstrated that the dynamics of antibody response induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) vaccines are different.

31 Aug 2021

Post-infection vaccination produces potent neutralizing antibodies against SARS-CoV-2 variants

The best protection against new SARS-CoV-2 infections or reinfections may be obtained by a combination of vaccine-elicited and infection-induced antibodies.

31 Aug 2021

J&J COVID-19 booster shot produces robust antibody response

The study showed neutralizing antibody responses produced by the Johnson & Johnson–Janssen vaccine was robust and stable eight months after immunization.

31 Aug 2021

The tale of mRNA vaccines: Turning calamity into opportunity

In a review paper published in the journal Nature Reviews, researchers from Carnegie Mellon University and the University of Pennsylvania have described the underlying technologies for mRNA vaccines and their future prospects with improved delivery systems and applications in diseases beyond the ongoing COVID-19 pandemic.

31 Aug 2021

Shorter survival of multiple myeloma subgroup linked to worse kidney damage

Nearly 20% of patients with multiple myeloma have a form in which they make extreme quantities of one component of the abnormal antibody they are producing, and these so-called "free monoclonal light chains" pile up and damage the kidneys, investigators say.

31 Aug 2021

Durability of cellular immune memory to SARS-CoV-2 after mRNA vaccination

A recent study, available on the bioRxiv* preprint server, investigated the durability of cellular immune memory after mRNA vaccination against SARS-CoV-2 and whether booster jabs affect the durability of different immune response components. The study included testing for antibodies and cellular immune responses in covid patients and recovered individuals.

31 Aug 2021

Monoclonal antibody treatment combo can reduce the impact of COVID-19 in high-risk patients

In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab - two monoclonal antibody treatments under Food and Drug Administration emergency use authorization - keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet's EClinicalMedicine.

31 Aug 2021

Scientists identify potential biomarkers to predict COVID-19 outcomes

A team of scientists from the United States has recently examined the trajectory of early immune biomarkers in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. They have identified specific plasma proteins that can accurately predict the clinical and virological outcomes in SARS-CoV-2 infected patients. The study is currently available on the medRxiv* preprint server.

31 Aug 2021

COVID-19 vaccine elicits antibody responses in nearly 9 out of 10 people taking immunosuppressants

COVID-19 vaccination elicited antibody responses in nearly nine out of 10 people with weakened immune systems, although their responses were only about one-third as strong as those mounted by healthy people, according to a study by researchers at Washington University School of Medicine in St. Louis.

30 Aug 2021

Prevalence of vaccine breakthrough cases in SF Bay Area

A new study focuse on studying breakthrough infections in a highly vaccinated community owing to the emergence of SARS-CoV-2 variants.

30 Aug 2021

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

A new study shows that the highly effective mRNA Moderna vaccine designed against the original SARS-CoV-2 strain may lose some efficacy as new variants arise.

30 Aug 2021

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

A new study adds to the data on the optimum interval between the first and second doses of the adenovirus vectored COVID-19 vaccine.

30 Aug 2021

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of SARS-CoV-2 stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion.

30 Aug 2021

CoronaVac elicits lower antibody response than natural SARS-CoV-2 infection, study suggests

A recent study from Thailand highlights a rather low degree of neutralization-afforded protection mounted by the inactivated whole-virus CoronaVac vaccine compared to natural infection with SARS-CoV-2 – the virus that causes COVID-19.

30 Aug 2021

New study maps the evolution of the SARS-CoV-2 delta and delta plus variants

The SARS-CoV-2 delta variant bears the D164G mutation, which is known to enhance viral fitness. However, a number of additional mutations are known to be common to the delta and delta plus lineages, at least 25 as identified in a study recently published in the Journal of Autoimmunity, mainly located on the spike protein of the virus.

30 Aug 2021

Next-gen COVID vaccine to make persistent neutralizing antibodies

Presently, there is a need to develop improved versions of COVID-19 vaccines that are effective against the SARS-CoV-2 variants of concern (VOC) and can confer long-term protection. Considering the need of the hour, scientists from the University of Sydney in Australia have generated a new COVID-19 vaccine CoVac-II and evaluated its effect against COVID-19 strains. The findings from this study are published on the bioRxiv* preprint server while awaiting peer review.

30 Aug 2021

Antibodies News and Research

Development of SARS-CoV-2 antibody escape variants in an immunocompromised individual

Does SARS-CoV-2 infection protect against reinfection?

Researchers identify biomarkers for rare, serious complication in children with COVID-19

$1.3 million in NIH funding to enable drug delivery technology research

mRNA COVID-19 vaccines induce high antibody titers with significant neutralizing potency in saliva

Post-infection vaccination produces potent neutralizing antibodies against SARS-CoV-2 variants

J&J COVID-19 booster shot produces robust antibody response

The tale of mRNA vaccines: Turning calamity into opportunity

Shorter survival of multiple myeloma subgroup linked to worse kidney damage

Durability of cellular immune memory to SARS-CoV-2 after mRNA vaccination

Monoclonal antibody treatment combo can reduce the impact of COVID-19 in high-risk patients

Scientists identify potential biomarkers to predict COVID-19 outcomes

COVID-19 vaccine elicits antibody responses in nearly 9 out of 10 people taking immunosuppressants

Prevalence of vaccine breakthrough cases in SF Bay Area

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

CoronaVac elicits lower antibody response than natural SARS-CoV-2 infection, study suggests

New study maps the evolution of the SARS-CoV-2 delta and delta plus variants

Next-gen COVID vaccine to make persistent neutralizing antibodies

How to make hybridoma-based antibody discovery more efficient eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News